Cellect Biotechnology Ltd. , a developer of stem cells isolation technology, announces today that it has received a formal notice of allowance around a key method of treatment patent from the United States Patent & Trademark Office. The allowed claims relate to the engineering of regulatory immune cells with enhanced apoptotic activity to be used for immunomodulation for treating or preventing immune related disorders.